Listed by the USPTO as DAHLE, CHUN WU
Tech Center 1600 • Art Units: 1641 1642 1643 1644 1671
This examiner grants 50% of resolved cases
Chun Wu Dahle serves in Tech Center 1600 and Art Unit 1641, having reached decisions on 666 resolved cases. The examiner's allowance rate stands at 50.2 percent. A notable metric for practitioners is the interview lift of 51.1 percent, which indicates that conducting an interview is associated with a higher likelihood of allowance than the 50.2 percent baseline rate. This suggests that the examiner is receptive to the clarifications and arguments typically presented during such sessions.
The median days to allowance for this examiner is 1438. Frequent applicants in this portfolio include Cantai Therapeutics Inc., INCYTE Corporation, and VIELA BIO, INC. These companies often utilize the services of firms such as COOLEY LLP, GREENBERG TRAURIG, LLP (BOS), and BakerHostetler to navigate the prosecution timeline. The combination of the 50.2 percent allowance rate and the 51.1 percent interview lift makes the decision to interview a critical component of the overall patent strategy for the 666 cases resolved by this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18011282 | FELINE ANTIBODY VARIANTS FOR IMPROVING STABILITY | Non-Final OA | Zoetis Services LLC |
| 18528382 | COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 19297947 | FC FRAGMENTS THAT BIND FCRN AND METHODS OF USE | Final Rejection | Paragon Therapeutics, Inc. |
| 18013864 | METHODS TO GLYCOENGINEER PROTEINS | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18033907 | GENETICALLY ENGINEERED ANTIGEN-SPECIFIC NATURAL KILLER CELLS FOR IN SITU SYNTHESIS OF PROTEINS | Final Rejection | SRI International |
| 18269257 | Method for Measuring Target Antigen, and Insoluble Particles and Kit for Target Antigen Measurement Used Therein | Final Rejection | Denka Company Limited |
| 17997171 | TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Final Rejection | Baylor College of Medicine |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | Final Rejection | Navigo Proteins GmbH |
| 18415031 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | Non-Final OA | Viela Bio, Inc. |
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | Final Rejection | Viela Bio, Inc. |
| 18507869 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF | Non-Final OA | GENMAB A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.2% of resolved applications examined by Chun Wu Dahle were allowed (666 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +51.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Chun Wu Dahle took 1,438 days on average from filing to allowance.
Chun Wu Dahle examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
